# Vertex Pharmaceuticals (VRTX) cash on hand: $6.61B in 2025

URL: https://funkfolio.com/stock/VRTX/cash

> Vertex Pharmaceuticals (VRTX) cash on hand was $6.61B at the end of fiscal 2025, up 8.0% from fiscal 2024. Year-by-year chart and table.

---

## Vertex Pharmaceuticals (VRTX) cash on hand

**Cash · fiscal 2025:** $6.61B at Dec 31, 2025

Vertex Pharmaceuticals (VRTX) held cash of $6.61B at the end of fiscal 2025 (December 31, 2025). That is 8.0% higher than the $6.12B of fiscal 2024. Figures as of 18 Nov 2026, 01:26 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Cash, fiscal 2025:** $6.61B
- **Change on fiscal 2024:** +8.0%
- **Highest on record:** $11.22B fiscal 2023
- **Lowest on record:** $6.12B fiscal 2024
- **Fiscal years on record:** 4 2022–2025

Figures as of 18 Nov 2026, 01:26 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Vertex Pharmaceuticals cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $11.22B in fiscal 2023 and the lowest $6.12B in fiscal 2024.

### Cash by fiscal year

### Vertex Pharmaceuticals cash on hand, year by year

Vertex Pharmaceuticals (VRTX) cash on hand by fiscal year

| Fiscal year | Cash | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $6.61B | 8.0% up | Dec 31, 2025 |
| 2024 | $6.12B | 45.5% down | Dec 31, 2024 |
| 2023 | $11.22B | 4.1% up | Dec 31, 2023 |
| 2022 | $10.78B | — | Dec 31, 2022 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

### How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

### Cash at health care companies of similar size

Cash of Vertex Pharmaceuticals and comparable companies

| Company | Cash | Fiscal year |
| --- | --- | --- |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/cash) | $13.60B | 2025 |
| [Danaher DHR](https://funkfolio.com/stock/DHR/cash) | $4.62B | 2025 |
| [Intuitive Surgical ISRG](https://funkfolio.com/stock/ISRG/cash) | $5.93B | 2025 |
| Vertex Pharmaceuticals VRTX | $6.61B | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/cash) | $9.22B | 2026 |
| [Bristol-Myers Squibb BMY](https://funkfolio.com/stock/BMY/cash) | $10.67B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Vertex Pharmaceuticals, figure by figure

- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals revenue](https://funkfolio.com/stock/VRTX/revenue)
- [Vertex Pharmaceuticals earnings](https://funkfolio.com/stock/VRTX/earnings)
- [Vertex Pharmaceuticals earnings per share (EPS)](https://funkfolio.com/stock/VRTX/eps)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals P/S ratio](https://funkfolio.com/stock/VRTX/ps-ratio)
- [Vertex Pharmaceuticals P/B ratio](https://funkfolio.com/stock/VRTX/pb-ratio)
- [Vertex Pharmaceuticals free cash flow](https://funkfolio.com/stock/VRTX/free-cash-flow)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals dividend](https://funkfolio.com/stock/VRTX/dividend)
- [Vertex Pharmaceuticals shares outstanding](https://funkfolio.com/stock/VRTX/shares-outstanding)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Vertex Pharmaceuticals total assets](https://funkfolio.com/stock/VRTX/total-assets)
- [Vertex Pharmaceuticals return on equity (ROE)](https://funkfolio.com/stock/VRTX/roe)
- [Vertex Pharmaceuticals return on invested capital (ROIC)](https://funkfolio.com/stock/VRTX/roic)

[Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecard](https://funkfolio.com/stock/VRTX) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Vertex Pharmaceuticals cash on hand: questions and answers

**How much cash does Vertex Pharmaceuticals have?**

Vertex Pharmaceuticals (VRTX) held cash of $6.61B at the end of fiscal 2025 (December 31, 2025). That is 8.0% higher than the $6.12B of fiscal 2024.

**What are the highest and lowest cash figures on record for Vertex Pharmaceuticals?**

Across the 4 fiscal years on record (2022–2025), the highest was $11.22B in fiscal 2023 and the lowest $6.12B in fiscal 2024.

**How is Vertex Pharmaceuticals's cash calculated?**

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

### Learn: cash on hand

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Market cap vs enterprise value: what is the difference?](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

  Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.
